Table 4 Patient demographics and oncological characteristics of patients started on SACT between 1st March to 31st May in 2020 during COVID-19 (with 2019 as a comparator)
2019 (n = 118) | 2020 (n = 102) | (n2020–n2019)/n2019 (%) | p value | |||||
|---|---|---|---|---|---|---|---|---|
n | % | n | % | |||||
Sex | N | |||||||
Male | 106 | 89.83 | 90 | 88.24 | 15.09 | 0.705 | ||
Age | ||||||||
Mean (SD)—years | 66.92 (12.16) | – | 65.12 (13.23) | – | – | – | ||
Socioeconomic status (IMD) | ||||||||
Low | 37 | 31.36 | 40 | 39.22 | − 8.11 | 0.223 | ||
Middle | 43 | 36.44 | 28 | 27.45 | 34.88 | 0.155 | ||
High | 38 | 32.20 | 33 | 32.35 | 13.16 | 0.981 | ||
Missing | 0 | 0.00 | 1 | 0.98 | N.A | 0.281 | ||
Ethnicity | ||||||||
White British | 44 | 37.29 | 29 | 28.43 | 34.09 | 0.164 | ||
White Other | 9 | 7.63 | 9 | 8.82 | 0.00 | 0.747 | ||
Black Caribbean | 9 | 7.63 | 5 | 4.90 | 44.44 | 0.409 | ||
Black African | 3 | 2.54 | 4 | 3.92 | − 33.33 | 0.561 | ||
Black Other | 0 | 0.00 | 1 | 0.98 | N.A | 0.281 | ||
Asian | 1 | 0.85 | 0 | 0.00 | 100.00 | 0.351 | ||
Mixed | 1 | 0.85 | 0 | 0.00 | 100.00 | 0.351 | ||
Other | 1 | 0.85 | 1 | 0.98 | 0.00 | 0.917 | ||
Unknown | 50 | 42.37 | 53 | 51.96 | − 6.00 | 0.155 | ||
Performance status (ECOG) | ||||||||
0 | 42 | 35.59 | 27 | 26.47 | 35.71 | 0.134 | ||
1 | 62 | 52.54 | 61 | 59.80 | 1.61 | 0.271 | ||
2 | 13 | 11.02 | 3 | 2.94 | 76.92 | 0.0214 | ||
3 | 1 | 0.85 | 0 | 0.00 | 100.00 | 0.368 | ||
Missing | 0 | 0.00 | 11 | 10.78 | N.A | 0.000216* | ||
Cancer type | ||||||||
Prostate | 74 | 62.71 | 57 | 55.88 | 22.97 | 0.303 | ||
Renal | 22 | 18.64 | 21 | 20.59 | 4.55 | 0.717 | ||
Urothelial | 14 | 11.86 | 17 | 16.67 | − 21.43 | 0.307 | ||
Testicular | 8 | 6.78 | 7 | 6.86 | 12.50 | 0.981 | ||
Stage | ||||||||
1 | 7 | 5.93 | 1 | 0.98 | 85.71 | 0.0504 | ||
2 | 4 | 3.39 | 5 | 4.90 | − 25.00 | 0.572 | ||
3 | 7 | 5.93 | 4 | 3.92 | 42.86 | 0.495 | ||
4 | 100 | 84.75 | 92 | 90.20 | 8.00 | 0.226 | ||
Missing | 0 | 0.00 | 0 | 0.00 | N.A | – | ||
SACT | ||||||||
Chemotherapy | 58 | 49.15 | 27 | 26.47 | 53.45 | 0.000674* | ||
Immunotherapy | 15 | 12.71 | 18 | 17.65 | − 20.00 | 0.230 | ||
PD-1/L1 | 11 | 9.32 | 15 | 14.71 | − 36.36 | – | ||
PD-1/L1 + CTLA-4 | 3 | 2.54 | 4 | 3.92 | − 33.33 | – | ||
Vaccine | 1 | 0.85 | 0 | 0.00 | 100.00 | – | ||
Hormone | 33 | 27.97 | 43 | 42.16 | − 30.30 | 0.0278 | ||
Novel hormone agents | 33 | 27.97 | 41 | 40.20 | − 24.24 | – | ||
Biological/targeted | 11 | 9.32 | 12 | 11.76 | − 9.09 | 0.689 | ||
Combo (Chemo/hormone) | 1 | 0.85 | 1 | 0.98 | 0.00 | 0.920 | ||
Combo (IO/target) | 0 | 0.00 | 1 | 0.98 | N.A | 0.271 | ||
Treatment paradigm | ||||||||
Neoadjuvant | 8 | 6.78 | 4 | 3.92 | 50.00 | 0.368 | ||
Adjuvant | 10 | 8.47 | 2 | 1.96 | 80.00 | 0.0357 | ||
Radical | 4 | 3.39 | 0 | 0.00 | 100.00 | 0.0574 | ||
Palliative | 95 | 80.51 | 90 | 88.24 | 5.26 | 0.110 | ||
Curative | 1 | 0.85 | 6 | 5.88 | − 500.00 | 0.0357 | ||
Line of palliative treatment (2019, n = 95; 2020, n = 90) | ||||||||
1 | 24 | 20.34 | 28 | 27.45 | − 16.67 | 0.376 | ||
2 | 49 | 41.53 | 50 | 49.02 | − 2.04 | 0.588 | ||
3 | 14 | 11.86 | 8 | 7.84 | 42.86 | 0.219 | ||
4 | 5 | 4.24 | 2 | 1.96 | 60.00 | 0.279 | ||
5 | 2 | 1.69 | 1 | 0.98 | 50.00 | 0.593 | ||
6 | 0 | 0.00 | 1 | 0.98 | N.A | 0.303 | ||
7 | 1 | 0.85 | 0 | 0.00 | 100.00 | 0.329 | ||
Trial treatment | ||||||||
Yes | 7 | 5.93 | 3 | 2.94 | 57.14 | 0.288 | ||
30-day mortality | 2 | 1.69 | 1 | 0.98 | 50.00 | 0.649 | ||
6-month mortality | 11 | 9.32 | 2 | 1.96 | 81.82 | 0.0209* | ||